Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Operating Expenses (2016 - 2025)

Amphastar Pharmaceuticals has reported Other Operating Expenses over the past 13 years, most recently at $19.0 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at $19.0 million for Q4 2025, up 82.32% from a year ago — trailing twelve months through Dec 2025 was $52.6 million (up 35.0% YoY), and the annual figure for FY2025 was $43.9 million, up 16.09%.
  • Other Operating Expenses for Q4 2025 was $19.0 million at Amphastar Pharmaceuticals, up from $11.5 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for AMPH hit a ceiling of $19.0 million in Q4 2025 and a floor of $4.1 million in Q4 2021.
  • Median Other Operating Expenses over the past 5 years was $6.9 million (2023), compared with a mean of $8.0 million.
  • Peak annual rise in Other Operating Expenses hit 82.32% in 2025, while the deepest fall reached 0.54% in 2025.
  • Amphastar Pharmaceuticals' Other Operating Expenses stood at $4.1 million in 2021, then soared by 34.28% to $5.5 million in 2022, then soared by 57.51% to $8.6 million in 2023, then increased by 20.94% to $10.4 million in 2024, then skyrocketed by 82.32% to $19.0 million in 2025.
  • The last three reported values for Other Operating Expenses were $19.0 million (Q4 2025), $11.5 million (Q3 2025), and $10.2 million (Q2 2025) per Business Quant data.